Proportion of ER+ disease by timing of receptor testing, North and sub-Saharan Africa.

<p>IBC, inflammatory breast cancer; LABC, non-IBC locally advanced breast cancer; N-IBC, non-inflammatory breast cancer. *These studies provided only a combined HR estimate for tumors that were either ER+ or PR+ <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001720#pmed.1001720-ElHawary1" target="_blank">[33]</a> or ER+ and/or PR+ (<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001720#pmed.1001720-Abbas1" target="_blank">[29]</a>; <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001720#pmed.1001720-Zeeneldin1" target="_blank">[43]</a>; <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001720#pmed.1001720-Hussein2" target="_blank">[52]</a>; <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001720#pmed.1001720-Boder1" target="_blank">[63]</a>; <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001720#pmed.1001720-Bouzid1" target="_blank">[64]</a>; <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001720#pmed.1001720-Salama1" target="_blank">[71]</a>).